Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Welcome to the 2nd European Lung Cancer Conference

Welcome to the 2nd European Lung Cancer Conference ABSTRACTS INTRODUCTION n behalf of The European Society for Medical Oncology clinical practice today. Our aim is to deliver an outstanding O(ESMO) and the International Association for the Study program with the right balance of clinical relevance, so an of Lung Cancer (IASLC), it gives us great pleasure to important part of the program covers the entire spectrum of welcome you to the 2nd European Lung Cancer Conference, practice issues in lung cancer. 28 April–1 May 2010 in Geneva, Switzerland. The Conference will discuss current trends in surgical, After a very successful inaugural Conference in 2008, radiotherapeutic and chemotherapeutic approaches to lung both Societies agreed that a regular scientific and educational cancer with ongoing focus on the individualization of therapy meeting in this area is important for providing a comprehen- based on clinical, histologic and molecular characteristics. sive overview of the most significant advances in lung cancer The Conference format is designed to enhance discussion research and treatment. Over the past few years, molecular about early stages of lung cancer from the aspect of different biology has revolutionized everything we have ever known potential treatments and combined modalities with specific about the natural history of this illness. Treatment must be questions about the role of surgery. The program also high- approached by multiple specialists and the strategy must be lights the role of radiation in lung cancer treatment and the tailored for every patient. As such attendees at this Confer- formidable development of new techniques such as stereo- ence will be joined by leading specialists from different tactic body, image-guided and intensity-modulated radiation latitudes of the world in order to exchange knowledge and therapy. The Conference will also feature presentations on experience. optimizing the application of established targeted agents as The program has interactive formats, which include well as presentations introducing emerging targeted agents, debates on controversial topics, educational and keynote including mechanisms of action and preclinical/clinical re- lectures, meet the expert sessions and specialty-specific nd sults. workshops. Attendance at this 2 European Lung Cancer We trust that participants will highly value the scope Conference will be a rewarding experience in enhancing and depth of the information on tumor biology, pathology, positive interactions between all lung cancer-related disci- prevention, early detection, epidemiology, tobacco control, plines. The Scientific Committee is delighted to be in a position to encourage poster sessions and discussions and oral imaging, staging, management-related issues and transla- presentations on perspectives, ideas, results and research tional and clinical research, presented with the emphasis on solutions submitted to promote an integrated approach to interdisciplinary challenges and supported by clinical inter- diagnosis and treatment of lung cancer. pretations needed for application of recent studies. In addition to the high quality scientific presentations, Our sincere thanks go to the members of the scientific the Committee introduced several improvements to the Con- committee, invited speakers, Conference organizers and ference program, with the aim of providing a comprehensive sponsors for their commitment to this Conference. We hope overview necessary for clinicians to fully understand how to that you enjoy the meeting and will already make a note in utilize and interpret advances in various molecular, genetic, your diary for the 3rd edition in 2012. pharmacogenomic, pathology and imaging methods and as- sessments; ensuring that the latest best practices and valuable Franc¸oise Mornex and Rafael Rosell key points/messages presented by the faculty can be put into Scientific Committee Co-Chairs S10 Journal of Thoracic Oncology  Volume 5, Number 5, Supplement 1, May 2010 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Welcome to the 2nd European Lung Cancer Conference

Journal of Thoracic Oncology , Volume 5 – May 1, 2010

Loading next page...
 
/lp/wolters-kluwer-health/welcome-to-the-2nd-european-lung-cancer-conference-AueDyszRfU
ISSN
1556-0864

Abstract

ABSTRACTS INTRODUCTION n behalf of The European Society for Medical Oncology clinical practice today. Our aim is to deliver an outstanding O(ESMO) and the International Association for the Study program with the right balance of clinical relevance, so an of Lung Cancer (IASLC), it gives us great pleasure to important part of the program covers the entire spectrum of welcome you to the 2nd European Lung Cancer Conference, practice issues in lung cancer. 28 April–1 May 2010 in Geneva, Switzerland. The Conference will discuss current trends in surgical, After a very successful inaugural Conference in 2008, radiotherapeutic and chemotherapeutic approaches to lung both Societies agreed that a regular scientific and educational cancer with ongoing focus on the individualization of therapy meeting in this area is important for providing a comprehen- based on clinical, histologic and molecular characteristics. sive overview of the most significant advances in lung cancer The Conference format is designed to enhance discussion research and treatment. Over the past few years, molecular about early stages of lung cancer from the aspect of different biology has revolutionized everything we have ever known potential treatments and combined modalities with specific about the natural history of this illness. Treatment must be questions about the role of surgery. The program also high- approached by multiple specialists and the strategy must be lights the role of radiation in lung cancer treatment and the tailored for every patient. As such attendees at this Confer- formidable development of new techniques such as stereo- ence will be joined by leading specialists from different tactic body, image-guided and intensity-modulated radiation latitudes of the world in order to exchange knowledge and therapy. The Conference will also feature presentations on experience. optimizing the application of established targeted agents as The program has interactive formats, which include well as presentations introducing emerging targeted agents, debates on controversial topics, educational and keynote including mechanisms of action and preclinical/clinical re- lectures, meet the expert sessions and specialty-specific nd sults. workshops. Attendance at this 2 European Lung Cancer We trust that participants will highly value the scope Conference will be a rewarding experience in enhancing and depth of the information on tumor biology, pathology, positive interactions between all lung cancer-related disci- prevention, early detection, epidemiology, tobacco control, plines. The Scientific Committee is delighted to be in a position to encourage poster sessions and discussions and oral imaging, staging, management-related issues and transla- presentations on perspectives, ideas, results and research tional and clinical research, presented with the emphasis on solutions submitted to promote an integrated approach to interdisciplinary challenges and supported by clinical inter- diagnosis and treatment of lung cancer. pretations needed for application of recent studies. In addition to the high quality scientific presentations, Our sincere thanks go to the members of the scientific the Committee introduced several improvements to the Con- committee, invited speakers, Conference organizers and ference program, with the aim of providing a comprehensive sponsors for their commitment to this Conference. We hope overview necessary for clinicians to fully understand how to that you enjoy the meeting and will already make a note in utilize and interpret advances in various molecular, genetic, your diary for the 3rd edition in 2012. pharmacogenomic, pathology and imaging methods and as- sessments; ensuring that the latest best practices and valuable Franc¸oise Mornex and Rafael Rosell key points/messages presented by the faculty can be put into Scientific Committee Co-Chairs S10 Journal of Thoracic Oncology  Volume 5, Number 5, Supplement 1, May 2010

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: May 1, 2010

There are no references for this article.